https://www.selleckchem.com/pr....oducts/daratumumab.h
1% cellular, 20.2% combined, 10.7% borderline). Among subjects without proteinuria or loss of eGFR ≥ 10ml/min/a (n = 34), 29 patients (85.3%) showed signs ofrejection (44.1% antibody mediated (ABMR), 14.7% cellular, 11.8% combined, 14.7% borderline). The majority of subjects with de novo DSA have histological signs of rejection, even in the absence of proteinuria and deterioration of graft function. Thus, it appears reasonable to routinely perform anallograft biopsy after thedetection of de novo DSA. The majority of subjects with de
Curtir
Comentario
Compartilhar
